Consumer Staples • Retail-Drug Stores and Proprietary Stores
$2.98 ▲ +0.01
(+0.34%)
MKT CAP: $26.2M • VOL: 100.4K
52W L $2 52W H $11
YI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.80B | $1.97B | $2.11B |
| YoY Revenue Growth % | -9.0% | -6.3% | — |
| Gross Profit | $103.4M | $113.6M | — |
| Gross Margin % | 5.8% | 5.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$340.0K | $289.0K | -$49.3M |
| Operating Margin % | 0.0% | 0.0% | -2.3% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | $168.8K | $2.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $17.0M | $36.0M | -$63.0M |
| Capital Expenditures (CapEx) | $636.0K | $2.1M | — |
| Free Cash Flow (FCF) | $16.4M | $34.0M | -$63.0M |
| FCF Margin % | 0.9% | 1.7% | -3.0% |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $73.1M | $63.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$100.4M | -$88.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR YI.